Protocol Ledger

NCT04567550 · Phase II · ACTIVE NOT RECRUITING

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Interventional Phase II clinical trial protocol NCT04567550 sponsored by AbbVie in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-20 Enrollment: 139 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04567550
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)139 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04567550
Protocol FieldVerified Registry Value
NCT IdentifierNCT04567550
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment139 participants (ACTUAL)
Registered Start Date2020-11-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04567550
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI